Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Anticancer Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Anticancer Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
      • 1.3.3 Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
      • 1.3.4 Hormonal Drugs
    • 1.4 Market Segment by Application
      • 1.4.1 Global Anticancer Drugs Market Share by Application (2019-2025)
      • 1.4.2 Lung Cancer
      • 1.4.3 Breast Cancer
      • 1.4.4 Leukemia
      • 1.4.5 Colorectal Cancer
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Anticancer Drugs Market Size
      • 2.1.1 Global Anticancer Drugs Revenue 2014-2025
      • 2.1.2 Global Anticancer Drugs Sales 2014-2025
    • 2.2 Anticancer Drugs Growth Rate by Regions
      • 2.2.1 Global Anticancer Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Anticancer Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Anticancer Drugs Sales by Manufacturers
      • 3.1.1 Anticancer Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Anticancer Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Anticancer Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Anticancer Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Anticancer Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Anticancer Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Anticancer Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Anticancer Drugs Market
    • 3.6 Key Manufacturers Anticancer Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Cytotoxic Drugs (Alkylating Agents, and Antimetabolites) Sales and Revenue (2014-2019)
      • 4.1.2 Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors) Sales and Revenue (2014-2019)
      • 4.1.3 Hormonal Drugs Sales and Revenue (2014-2019)
    • 4.2 Global Anticancer Drugs Sales Market Share by Type
    • 4.3 Global Anticancer Drugs Revenue Market Share by Type
    • 4.4 Anticancer Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Anticancer Drugs Sales by Application

    6 United States

    • 6.1 United States Anticancer Drugs Breakdown Data by Company
    • 6.2 United States Anticancer Drugs Breakdown Data by Type
    • 6.3 United States Anticancer Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Anticancer Drugs Breakdown Data by Company
    • 7.2 European Union Anticancer Drugs Breakdown Data by Type
    • 7.3 European Union Anticancer Drugs Breakdown Data by Application

    8 China

    • 8.1 China Anticancer Drugs Breakdown Data by Company
    • 8.2 China Anticancer Drugs Breakdown Data by Type
    • 8.3 China Anticancer Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Anticancer Drugs Breakdown Data by Company
    • 9.2 Rest of World Anticancer Drugs Breakdown Data by Type
    • 9.3 Rest of World Anticancer Drugs Breakdown Data by Application
    • 9.4 Rest of World Anticancer Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Anticancer Drugs Sales by Countries
      • 9.4.2 Rest of World Anticancer Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 F. Hoffmann-La Roche Ltd
      • 10.1.1 F. Hoffmann-La Roche Ltd Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.1.4 Anticancer Drugs Product Introduction
      • 10.1.5 F. Hoffmann-La Roche Ltd Recent Development
    • 10.2 Eli Lilly and Company
      • 10.2.1 Eli Lilly and Company Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.2.4 Anticancer Drugs Product Introduction
      • 10.2.5 Eli Lilly and Company Recent Development
    • 10.3 CELGENE CORPORATION
      • 10.3.1 CELGENE CORPORATION Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.3.4 Anticancer Drugs Product Introduction
      • 10.3.5 CELGENE CORPORATION Recent Development
    • 10.4 Novartis AG
      • 10.4.1 Novartis AG Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.4.4 Anticancer Drugs Product Introduction
      • 10.4.5 Novartis AG Recent Development
    • 10.5 Pfizer Inc
      • 10.5.1 Pfizer Inc Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.5.4 Anticancer Drugs Product Introduction
      • 10.5.5 Pfizer Inc Recent Development
    • 10.6 Amgen Inc
      • 10.6.1 Amgen Inc Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.6.4 Anticancer Drugs Product Introduction
      • 10.6.5 Amgen Inc Recent Development
    • 10.7 Bayer AG
      • 10.7.1 Bayer AG Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.7.4 Anticancer Drugs Product Introduction
      • 10.7.5 Bayer AG Recent Development
    • 10.8 AstraZeneca
      • 10.8.1 AstraZeneca Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.8.4 Anticancer Drugs Product Introduction
      • 10.8.5 AstraZeneca Recent Development
    • 10.9 Takeda Pharmaceutical Company Limited
      • 10.9.1 Takeda Pharmaceutical Company Limited Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.9.4 Anticancer Drugs Product Introduction
      • 10.9.5 Takeda Pharmaceutical Company Limited Recent Development
    • 10.10 Merck & Co.
      • 10.10.1 Merck & Co. Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Anticancer Drugs
      • 10.10.4 Anticancer Drugs Product Introduction
      • 10.10.5 Merck & Co. Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Anticancer Drugs Sales Channels
      • 11.2.2 Anticancer Drugs Distributors
    • 11.3 Anticancer Drugs Customers

    12 Market Forecast

    • 12.1 Global Anticancer Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Anticancer Drugs Sales Forecast by Type
    • 12.3 Global Anticancer Drugs Sales Forecast by Application
    • 12.4 Anticancer Drugs Forecast by Regions
      • 12.4.1 Global Anticancer Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Anticancer Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Antineoplastic drugs, also known as anticancer drugs, anti-malignant drugs, refer to drugs for the treatment of malignant tumors.
      Simply put, there are chemotherapy drugs and biological agents. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of tumors; the invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry, and genetic engineering have accelerated the process of drug development; research and development of anti-tumor drugs have been Enter a new era.
      At present, there are more than 80 kinds of anti-cancer drugs commonly used in clinical practice in the world, which can be roughly divided into the following 6 categories: cytotoxic drugs, hormone drugs, biological response modifiers, monoclonal antibody drugs, other drugs, and auxiliary drugs.
      In 2019, the market size of Anticancer Drugs is 89300 million US$ and it will reach 163400 million US$ in 2025, growing at a CAGR of 7.9% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Anticancer Drugs.

      This report studies the global market size of Anticancer Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Anticancer Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      F. Hoffmann-La Roche Ltd
      Eli Lilly and Company
      CELGENE CORPORATION
      Novartis AG
      Pfizer Inc
      Amgen Inc
      Bayer AG
      AstraZeneca
      Takeda Pharmaceutical Company Limited
      Merck & Co.

      Market Segment by Product Type
      Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
      Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
      Hormonal Drugs

      Market Segment by Application
      Lung Cancer
      Breast Cancer
      Leukemia
      Colorectal Cancer

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Anticancer Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Anticancer Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Anticancer Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now